Related Experiment Video

Updated: Mar 28, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

11.3K

Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor

Michael Tang1, Jun Diao1, Hongtao Gu1

  • 1Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Cell Reports
|December 30, 2015
PubMed

Insights

Tumor-derived TLR2 ligands cause immunosuppressive dendritic cells (DCs) in cancer, hindering immunity. Blocking TLR2 enhances DC function and immunotherapy effectiveness, revealing a new therapeutic target.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Mechanisms

Background:

  • Dendritic cell (DC) dysfunction is a known factor in cancer immune evasion, driven by inflammation.
  • The precise molecular mechanisms underlying DC dysfunction in the tumor microenvironment remain unclear.

Purpose of the Study:

  • To elucidate the mechanisms by which tumor-derived factors induce immunosuppressive DCs.
  • To identify novel therapeutic targets for enhancing anti-cancer immunity.

Main Methods:

  • Investigated the role of Toll-like receptor 2 (TLR2) ligands in DC function using human and mouse models.
  • Analyzed the activation of Signal Transducer and Activator of Transcription 3 (STAT3) pathway.
  • Identified versican as a tumor-derived TLR2 ligand.
  • Evaluated the impact of TLR2 blockade on anti-tumor immunity and immunotherapy efficacy in vivo.

Main Results:

  • Tumor-derived TLR2 ligands are critical for generating immunosuppressive, IL-10-producing DCs.
  • TLR2 activation leads to synergistic STAT3 activation via autocrine IL-6/IL-10 signaling and receptor upregulation.
  • Versican was identified as a key tumor-derived factor that activates TLR2 on DCs.
  • In vivo blockade of TLR2 enhanced DC immunogenicity and improved immunotherapy outcomes.

Conclusions:

  • Tumor-derived TLR2 ligands drive DC dysfunction and immunosuppression in cancer.
  • Targeting TLR2 offers a promising strategy to restore DC function and enhance cancer immunotherapy.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.8K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.3K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K